Use of PCSO-524® and Cyclosporin for Treatment of Immune-Mediated Polyarthritis in Dogs

Antinol® Cases Study 2020 Content

1st Winning Award

PCSO-524® for Treatment of Immune-Mediated Polyarthritis in Dogs

Irin Kwananocha, DVM, Small Animal Hospital, Chulalongkorn University

Abstract

An 8 years old Chihuahua dog was admitted to the Small Animal Hospital at Chulalongkorn University due to signs of depression, lethargy, lameness and joint effusion. Hematological examination and test of synovial fluid indicated Immune-Mediated Polyarthritis (IMPA). 

Prednisolone, Gabapentin and Amoxillin-clavulanic acid were prescribed for the treatment. Abnormally increase of ALT, ALK and AST enzyme was observed 1 week later, therefore, the treatment was changed to Cyclosporin, Gabapetin, and PCSO-524®. The clinical signs continued to improve after the adjustment of prescription and Cyclosporin and Gabapetin were terminated after 3 and 4 months, respectively. 

A follow-up examination at 4 months later showed no signs of lameness and joint effusion and no adverse effects caused by the long-term use of PCSO-524®. 

The success of IMPA treatment is a result of rapid diagnosis and appropriate treatment protocol. Follow-up for treatment evaluation is necessary during the treatment course in order to reduce the impact on health and minimize the medication dosage without risk of causing adverse effects or recurrence of the disease. 

Keywords: Cyclosporin, dog, Immune Mediated Polyarthritis, PCSO-524®